WARRINGTON, Pa., Dec. 1, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that two abstracts have been accepted for presentation at the Hot Topics in Neonatology conference being held December 5 – 7, 2016 in Washington, DC. For over 30 years, Hot Topics has been a premiere neonatal conference, with more than 1000 neonatologists and perinatologists from around the world attending each year.
Summarized below are the abstract titles and presentation times. The Hot Topics in Neonatology posters are embargoed until presentation time, but once presented, will be available on the Windtree Therapeutics website – www.windtreetx.com.
Timothy J. Gregory, Ph.D., Senior Director, Clinical and Pre-Clinical Science, at Windtree will present Deposition of Aerosolized Lucinactant in Non-Human Primates from 5:45 pm to 6:45 pm on December 5, 2016.
Paul M Shore, M.D., M.S., Senior Director, Clinical Research, at Windtree will present Wide Variation in Rate and Timing of Endotracheal Intubation (ETI) in Preterm Neonates with Respiratory Distress Syndrome (RDS) from 5:45 pm to 6:45 pm on December 5, 2016.
Windtree's lead product candidate is AEROSURF® (lucinactant for inhalation), a novel, investigational combination drug/device product that combines the Company's proprietary KL4 surfactant and aerosolization technologies. AEROSURF is being developed to potentially reduce or eliminate the need for endotracheal intubation and mechanical ventilation in the treatment of premature infants with RDS. Enrollment is ongoing in a phase 2b clinical trial to study AEROSURF administered to premature infants 29 to 32 week GA receiving nasal continuous positive airway pressure (nCPAP) for RDS, compared to infants receiving nCPAP alone.
About Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants and believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies.
For more information, please visit the Company's website at www.windtreetx.com.
Logo - http://photos.prnewswire.com/prnh/20160415/356055LOGO
SOURCE Windtree Therapeutics, Inc.